Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

被引：0

作者：

Costa, Luciano ^{[1
]}

Bar, Noffar ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
]}

Paris, Laura ^{[6
]}

Hofmeister, Craig ^{[7
]}

Rodriguez-Otero, Paula

Bermudez, Maria Aranzazu ^{[9
]}

Santoro, Armando ^{[8
,10
]}

Yee, Andrew ^{[11
]}

Creignou, Maria ^{[12
]}

Encinas, Cristina ^{[13
]}

Cerchione, Claudio ^{[14
]}

de la Rubia, Javier ^{[15
]}

Oriol, Albert ^{[16
]}

Ferstl, Barbara ^{[17
]}

Besemer, Britta ^{[18
]}

Chen, Jinjie ^{[19
]}

Boss, Isaac ^{[19
]}

Gaudy, Allison ^{[19
]}

Hsu, Kevin ^{[19
]}

Godwin, Colin ^{[19
]}

San-Miguel, Jesus ^{[20
]}

Wong, Sandy ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] ASST Papa Giovanni XXIII, Bergamo, Italy

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[9] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[10] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain

[14] Ist Scientif Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[15] Univ Hosp La Fe, Dept Hematol, Valencia, Spain

[16] Hosp Germans Trias i Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain

[17] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[18] Univ Tubingen Hosp, Tubingen, Germany

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] Inst Invest Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Canc Ctr Clin Univ Navarra, Pamplona, Spain

[21] Univ Calif San Francisco, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-033

引用

页码：S52 / S53

页数：2

共 50 条

[1] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.
Bar, Noffar
Paris, Laura
Hofmeister, Craig C.
Hansson, Markus
Santoro, Armando
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Lund, Johan
Encinas, Cristina
Yee, Andrew J.
Oriol, Albert
Cerchione, Claudio
de la Rubia, Javier
Ferstl, Barbara
Carlson, Kristina
Ribas, Paz
Bermudez, Arancha
Boss, Isaac W.
Gaudy, Allison
Li, Shaoyi
Hsu, Kevin
Godwin, Colin D.
Burgess, Michael R.
San-Miguel, Jesus
Costa, Luciano J.
BLOOD, 2022, 140
[2] Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar
Victoria Mateos, Maria
Ribas, Paz
Hansson, Markus
Paris, Laura
Hofmeister, Craig C.
Rodriguez Otero, Paula
Aranzazu Bermudez, Maria
Martin, Thomas
Santoro, Armando
Yee, Andrew J.
Creignou, Maria
Encinas Rodriguez, Cristina
Cerchione, Claudio
De La Rubia, Javier
Oriol, Albert
Waibel, Heidi
Besemer, Britta
Thompson, Ethan
Kiesel, Brian
Chen, Jinjie
Chung, Alexander
Boss, Isaac W.
Gaudy, Allison
Li, Shaoyi
Hsu, Kevin
Godwin, Colin
Burgess, Michael R.
San-Miguel, Jesus
Costa, Luciano
BLOOD, 2023, 142
[3] Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models
Paiva, Bruno
Gaffney, Bonny
Burnett, Kelven
Castiglioni, Paola
La Motte-Mohs, Ross
Angelo, Michael
Pierce, Daniel
Boss, Isaac
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S46 - S47
[4] Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models
Paiva, Bruno
Gaffney, Bonny
Burnett, Kelven
Castiglioni, Paola
Angelo, Michael
Pierce, Daniel W.
Boss, Isaac W.
BLOOD, 2022, 140 : 7054 - 7055
[5] Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Boss, Isaac W.
Thompson, Ethan
Gaudy, Allison M.
Vu, Minh Diem
Godwin, Colin D.
Burgess, Michael R.
Wong, Sandy W.
Costa, Luciano J.
BLOOD, 2022, 140 : 7116 - 7117
[6] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Costa, Luciano J.
Wong, Sandy W.
Bermudez, Arancha
de la Rubia, Javier
Mateos, Maria-Victoria
Ocio, Enrique M.
Rodriguez-Otero, Paula
San-Miguel, Jesus
Li, Shaoyi
Sarmiento, Rafael
Lardelli, Pilar
Gaudy, Allison
Boss, Isaac
Kelly, Lisa M.
Burgess, Michael R.
Hege, Kristen
Bensinger, William I.
BLOOD, 2019, 134
[7] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
Voorhees, Peter
Shah, Nina
D'Souza, Anita
Rodriguez, Cesar
Weisel, Katja
Teipel, Raphael
Hurd, David
Bueno, Orlando
Pumford, Neil
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Ross, Jeremy
Polepally, Akshanth
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Kumar, Shaji
Vij, Ravi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34
[8] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Kumar, Shaji
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Bueno, Orlando F.
Ben Buelow
Freise, Kevin J.
Yue, Susan
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Vij, Ravi
BLOOD, 2021, 138
[9] Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Vij, Ravi
Kumar, Shaji Kunnathu
D'Souza, Anita
Mckay, John T.
Voorhees, Peter M.
Chung, Alfred
Tuchman, Sascha Alexander
Korde, Neha
Weisel, Katja
Teipel, Raphael
Bueno, Orlando
Feng, Zhongling
Rosenberg, Tanya S.
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Lee, Shane
Jin, Ziyi
Ross, Jeremy A.
Ahsan, Aarif
Talati, Chetasi
Rodriguez, Cesar
BLOOD, 2023, 142
[10] A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Hurd, David Duane
Teipel, Raphael
Chung, Alfred
Rodriguez, Cesar
Tuchman, Sascha A.
Korde, Neha
Safah, Hana
Bueno, Orlando F.
Pumford, Neil
Rosenberg, Tanya S.
Pothacamury, Rajvineeth Kumar
Ross, Jeremy A.
Polepally, Akshanth R.
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Vij, Ravi
Kumar, Shaji K.
BLOOD, 2022, 140 : 4401 - 4404

← 1 2 3 4 5 →